Anika Therapeutics names CMO, COO
April 4, 2016Sales and Marketing Anika Therapeutics, CMO, COO, Executive appointment
Anika Therapeutics (Nasdaq: ANIK) on Monday named the executive appointments of Stephen Mascioli the chief medical officer (CMO) and Dana …
Eisai’s Halaven recommended for European approval
April 4, 2016Research and Development, Sales and Marketing Eisai, Halaven, liposarcoma
Eisai has received a positive opinion from the European Commission’s CHMP for Halaven (eribulin) as a second-line therapy for patients …
Weekly Movers: Lupin, Natco Pharma, Keryx, Puma Biotech
April 4, 2016Research and Development, Sales and Marketing
Another week of big gains and some major losses has come to pass. While the Indian pharma sector continues to …
Research shows Novartis’s Entresto reduces cardiovascular death and heart failure
April 4, 2016Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent
Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …
Takeda, Teva name Hiroshi Matsumori CEO of Japanese generic drug joint venture
April 4, 2016Business Services, Sales and Marketing CEO Appointment, Takeda, Teva, joint venture
Japanese drug firm Takeda (TYO: 4502) and Israel-based Teva (NYSE: TEVA) named Hiroshi Matsumori the chief executive for their newly-formed …
Amicus Therapeutics’ Fabry disease drug gets European regulatory support
April 4, 2016Research and Development, Sales and Marketing Amicus Therapeutics, EMA, Fabry disease, genetic disorder, rare disease
Shares in biotechnology firm Amicus Therapeutics (Nasdaq: FOLD) rose to close up nearly 3% after the European regulators announced backing …
Novo says Victoza bests MSD’s Januvia at lowering blood sugar
April 4, 2016Research and Development Novo Nordisk, Victoza
Novo Nordisk says its diabetes drug Victoza, in combination with metformin, outperformed MSD’s Januvia plus metformin in reducing HbA1c – …
Amgen’s high cholesterol drug at centre of patent court case yields positive clinical trial results
April 4, 2016Research and Development, Sales and Marketing Amgen, Repatha, Sanofi, high cholesterol. ldl, ldl-c, phase III, statins
Amgen has announced positive results from the Phase III GAUSS-3 clinical trial evaluating Repatha (evolucumab) in patients with high cholesterol …
GSK’s gene therapy for rare condition in children gets EMA backing
April 4, 2016Research and Development, Sales and Marketing ADA-SCID, European Medicines Agency, GlaxoSmithKline, Orphan Therapy, Rare Treatment, drug trial, gene therapy
UK drug major GlaxoSmithKline (LSE: GSK) has won marketing recommendation from European regulators for its first gene therapy to treat …
Timeline of turmoil – Valeant Pharmaceuticals’ troubled March 2016
April 4, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Share price, Valeant, fall, month from hell, timeline, turmoil
As far as months go, March 2016 couldn’t have gone much worse for Valeant Pharmaceuticals. The Canada-based company has been …
Two CHMP nods for Janssen
April 4, 2016Research and Development, Sales and Marketing Xeplion, darzalex, multiple myeloma
The European Commission’s scientific committee has recommended Janssen’s Darzalex (daratumumab) for multiple myeloma and Trevicta (paliperidone palmitate) for maintenance treatment …
Sanofi’s dengue vaccine rolled out for world’s first public immunisation program
April 4, 2016Sales and Marketing Philippines, Sanofi, Vaccine, children, dengue, dengvaxia, immunisation, prevention, public health
Sanofi, along with its vaccines global business unit Sanofi Pasteur, has announced the beginning of the first public dengue immunisation …
Daiichi Sankyo names Antoine Yver global head of oncology research and development
April 1, 2016Business Services, Medical Communications Daiichi Sankyo, Japan, appointment
Japanese drug major Daiichi Sankyo (TYO: 4568) on Friday named Antoine Yver, global head, oncology research and development, effective April …
Pfizer’s cholesterol-lowering bococizumab shows promise in Phase III trials
April 1, 2016Research and Development, Sales and Marketing Pfizer, bococizumab, lipid, phase 3, phase III, spire, spire-ai
Pfizer (NYSE: PFE) has announced positive top line results from the SPIRE-AI Phase III clinical trial evaluating bococizumab. This protein …
FTC files complaint against Endo for blocking generics of its pain drugs
April 1, 2016Business Services, Manufacturing and Production, Medical Communications, Sales and Marketing Endo International, FTC, legal, regulation
The US Federal Trade Commission (FTC) has filed a complaint against Endo International (Nasdaq: ENDP) alleging the company used illegal …
FDA to review investigational hepatitis B vaccine
April 1, 2016Medical Communications, Research and Development dynavax, hepatitis B, vaccines
Dynavax Technologies (NASDAQ: DVAX) says the FDA has accepted for review the company’s investigational adult hepatitis B vaccine, HEPLISAV-B. The FDA has set …
Whistleblower accuses Novartis of paying bribes in Turkey to push sales
April 1, 2016Business Services, Medical Communications, Sales and Marketing Financial, Novartis, legal, reuters
An anonymous whistleblower has accused Swiss drugmaker Novartis (SIX: NOVN) of paying bribes in Turkey through a consulting firm to …
Janssen to stop fulranumab development in osteoarthritis pain
April 1, 2016Medical Communications, Research and Development, Sales and Marketing Amgen, Janssen
Janssen says it is discontinuing Phase III development for fulranumab in osteoarthritis pain. The J&J company says the decision is …
Fake press release on drug pricing “erroneously attributed” to Pfizer
April 1, 2016Medical Communications Pfizer, fake, false, legal action, press release, washington post
Pfizer (NYSE: PFE) has issued a statement on a false press release related to drug pricing that was reported on …
FDA releases biosimilars labelling guidance
April 1, 2016Manufacturing and Production, Medical Communications, Research and Development FDA, biosimilars
The US Food and Drug Administration (FDA) has issued draft guidance on the labelling of biosimilar drugs. The guidance states …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEO
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
